Stock Hotlist: Three Picks for the Week Ahead

Picking the wrong stocks can decimate your portfolio.

They’re pure portfolio poison.  

But the right stocks…

If you pick the right stocks, you could find yourself jumping for joy on top of an enormous pile of cash.

With over 4000 tickers to choose from, finding the right stock at the right time can prove to be nearly impossible… 

Unless you’re spending hours each day combing the markets and researching companies.  

That’s why we’ve done the legwork for you.  

We sort through thousands of stock ideas and whittle them down to a few top choices that are primed for solid price action in the coming days, weeks and months.  

This week, we’ve narrowed it down to three stocks that could be getting significant attention in the near future.

Click here for the full story on the stocks we’re watching this week… 

Torm (TRMD)

TORM is one of the world’s largest owners and operators of product tankers that transport refined oil products and chemicals. Torm stands out among peers, with its strategic focus on high-value trades and key regions, backed by its integrated One Torm platform. This approach has not only garnered robust customer support but also enables the company to access lucrative cargo combinations, crucial for maximizing fleet efficiency and profit potential.

At its core, Torm is adept at leveraging geopolitical shifts that impact global trade flows. A prime example is the EU’s ban on Russian oil products, which has reshuffled trade routes towards longer distances. This shift is a boon for Torm, driving up freight rates and market volatility – both key indicators of a potentially profitable environment.

Looking ahead, Torm is poised for a strong Q4. The company is banking on factors like Europe’s dwindling diesel stocks, wider arbitrage spreads, and a surge in long-haul trade flows. Additionally, with global oil demand hitting new peaks and the evolving refinery landscape, especially in the Middle East, Torm is well-positioned to tap into sustained growth opportunities. For investors focused on the long game, Torm represents a compelling watch in the coming months and beyond.

[stock_market_widget type=”accordion” template=”extended” color=”#5679FF” assets=”TORM” start_expanded=”true” api=”yf”]

Colgate-Palmolive (NYSE: CL)

In the realm of steady, dependable stocks, Colgate-Palmolive stands out as a particularly unexciting yet reliable choice. Known primarily for its toothcare and cleaning products, Colgate-Palmolive also delves into a variety of other areas, including deodorants, skincare, and even high-end pet food. Considering America’s unwavering love for pets, even in tough times, CL is a solid bet for investors looking for stability.

However, it’s important to note that CL isn’t completely shielded from downturns. Since the beginning of the year, the company has seen a slight dip of over 2% in its equity value. But, there’s a silver lining – in the past month, CL has rebounded, showing an upward swing of more than 7%. This uptick is largely attributed to the company’s strong performance in its third-quarter earnings.

Delving into the numbers, Colgate-Palmolive posted earnings per share of 86 cents, surpassing the anticipated 80 cents. Revenue also exceeded expectations, coming in at $4.82 billion against the forecasted $4.7 billion. The fundamental outlook remains positive, as the demand for everyday essentials like toothpaste isn’t going away anytime soon.

Market analysts currently rate CL as a moderate buy, with a target price of $81.57. When you factor in its potential for passive income, Colgate-Palmolive emerges as a reassuring option for those compiling a list of stocks to buy, especially for those seeking a blend of safety and modest growth potential.

[stock_market_widget type=”accordion” template=”extended” color=”#5679FF” assets=”CL” start_expanded=”true” api=”yf”]

Hims & Hers Health (HIMS)

Despite a challenging year marked by a 28% decline, HIMS has made a significant rebound. The company’s third-quarter results are impressive, boasting a revenue jump to $226.7 million, a striking 57% increase year-over-year. With a growing subscriber base now at 1.4 million, HIMS is clearly expanding its influence in the market.

Hims & Hers Health isn’t just resting on its laurels. The company is strategically branching out, notably into the weight loss market by the end of 2023. This expansion, along with innovative strides in cardiovascular health and MedMatch technology, cements HIMS as a telehealth stock to keep on your radar. Its diversification across various health sectors shows a dynamic and forward-thinking approach.

Financially, Hims & Hers Health is showing signs of robust strength. The launch of a $50 million share repurchase program is a strong vote of confidence in its financial stability. The company’s revenue forecast for 2023, estimated between $868 million and $873 million, mirrors its ambitious growth plans. This, coupled with a solid EBITDA outlook, further solidifies HIMS’s standing in the telehealth market.

In summary, Hims & Hers Health is shaping up to be an attractive pick for investors eyeing the telehealth space. With its diverse healthcare initiatives, strong financials, and strategic market positioning, HIMS is not just a company to watch but a potential leader in the evolving world of telehealth. For those looking to invest in innovative healthcare stocks, HIMS is certainly worth considering, offering both growth potential and a pioneering spirit in the industry.

[stock_market_widget type=”accordion” template=”extended” color=”#5679FF” assets=”HIMS” start_expanded=”true” api=”yf”]